The raised guidance signals accelerating commercial traction for Amtagvi and Proleukin. Watch Q3 2026 earnings in early November for confirmation of the trajectory and any updates on ATC expansion or pipeline milestones.
Price Chart
Executive Summary
Iovance Biotherapeutics raised its full year 2026 total revenue guidance to $410–$420 million, up from the prior range of $350–$370 million, driven by strong U.S. demand for Amtagvi and Proleukin. The midpoint increase of $55 million (~15%) implies nearly 60% annual revenue growth. This is a clear positive catalyst reflecting accelerating commercial adoption and improved visibility into H2 2026 revenue.
Key Facts
- FY 2026 revenue guidance raised to $410–$420 million from $350–$370 million
- Midpoint increase of $55 million, or ~15%, over prior guidance
- Implies nearly 60% annual total revenue growth
- Driven by strong U.S. demand for Amtagvi (lifileucel) and Proleukin
- Record Q2 2026 total product revenue of $99.3 million
- ATC network grown to ~100 centers, on track for at least 110 by year-end 2026
- Q3 2026 results expected in early November 2026
Financial Impact
FY 2026 revenue guidance raised by $55 million at midpoint to $410–$420 million; Q2 2026 product revenue was a record $99.3 million
Risk Factors
- Guidance assumes no material change in manufacturing ability, payor coverage, or revenue recognition policies
- Dependence on continued demand growth for Amtagvi and Proleukin
- Forward-looking statements subject to risks including commercialization, regulatory, and competitive factors
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-111583 |
| Document: tm2626507d1_ex99-1.htm | 0001104659-26-111583 |
| Document: 0001104659-26-111583-index-headers.html | 0001104659-26-111583 |
| Document: 0001104659-26-111583-index.html | 0001104659-26-111583 |
| Document: 0001104659-26-111583.txt | 0001104659-26-111583 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 21d ago | 8-K | $12.96 $12.92 | ▼ −0.31% | ▼ −0.07% | $13.76 (+6.17%) |
Oct 2, 2026 24d ago | 3 | $14.15 $12.96 | ▼ −8.41% | ▼ −8.96% | $13.76 (−2.76%) |
Sep 29, 2026 28d ago | 8-K | $14.45 $14.82 | ▲ +2.56% | ▲ +2.77% | $13.76 (−4.78%) |
Aug 21, 2026 9w ago | Press Release | $8.06 $8.44 | ▲ +4.71% | ▲ +4.39% | $13.76 (+70.72%) |
Aug 6, 2026 11w ago | 8-K | $6.34 $6.40 | ▲ +0.95% | ▲ +0.98% | $13.76 (+117.03%) |
Aug 6, 2026 11w ago | 8-K | $6.21 $6.34 | ▲ +2.09% | ▲ +1.48% | $13.76 (+121.58%) |
Jul 16, 2026 14w ago | Court Ruling | $5.00 $5.02 | ▼ −0.40% | ▼ −0.56% | $13.76 (−175.20%) |
Jul 2, 2026 16w ago | 8-K | $4.31 $4.19 | ▼ −2.78% | ▼ −3.66% | $13.76 (+219.26%) |
Jun 19, 2026 18w ago | Press Release | $4.06 $4.44 | ▲ +9.36% | ▲ +10.81% | $13.76 (+238.92%) |
Jun 18, 2026 18w ago | S-3ASR | $4.06 $4.44 | ▲ +9.36% | ▲ +10.81% | $13.76 (+238.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers